BioCryst Pharmaceuticals, Inc.
BCRX
$9.81
$0.657.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 245.85M | 12.90M | 5.09M | 32.00K | -26.80M |
| Total Depreciation and Amortization | 2.49M | 335.00K | 329.00K | 331.00K | 2.08M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 39.40M | 29.76M | 33.51M | 34.25M | 30.84M |
| Change in Net Operating Assets | 4.23M | -1.37M | 2.38M | -62.13M | -11.33M |
| Cash from Operations | 291.96M | 41.62M | 41.30M | -27.52M | -5.21M |
| Capital Expenditure | -802.00K | -1.34M | -179.00K | -143.00K | -675.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 550.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -6.18M | -- | -- | -- | -- |
| Other Investing Activities | -76.50M | 14.37M | 29.31M | 27.24M | 18.47M |
| Cash from Investing | -83.49M | 13.57M | 29.13M | 27.10M | 17.80M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -197.14M | -60.85M | -76.25M | -516.00K | -356.00K |
| Issuance of Common Stock | 680.00K | 2.67M | 3.43M | 2.40M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -581.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -21.50M | -628.00K | -866.00K | -1.35M | -3.08M |
| Cash from Financing | -217.96M | -58.81M | -73.69M | 529.00K | -4.02M |
| Foreign Exchange rate Adjustments | -72.00K | -468.00K | 1.36M | 451.00K | -1.30M |
| Miscellaneous Cash Flow Adjustments | 14.84M | 218.00K | -15.06M | -- | -- |
| Net Change in Cash | 5.28M | -3.87M | -16.96M | 558.00K | 7.26M |